Drug Trial Radar · NCT06672900
A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Feb 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
24
Actual
Start
Jan 9, 2025
Primary completion
Jul 7, 2025
Study completion Jul 7, 2025
Sponsor
- Lead sponsor
- Aligos TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Nov 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase 1 study consists of two parts, all conducted in healthy volunteers (HVs). In Part 1, the drug-drug interaction (DDI) potential of ALG-000184 will be explored with Itraconazole; participants will be assigned to receive multiple doses of ALG-000184 and Itraconazole over a two week period. In Part 2, the drug-drug interaction (DDI) potential of ALG-000184 will be explored with Carbamazepine; participants will be assigned to receive multiple doses of ALG-000184 and ascending doses of Carbamazepine over an 18 day period. The 2 parts may be conducted in parallel.
Conditions
- Healthy Volunteer
Interventions
CarbamazepineDrug
Commercially available supply.
Itraconazole (Sporanox)Drug
Commercially available supply.
ALG-000184Drug
Study Investigational Product
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the concentration time curve [AUC]Time frame: Up to 24 days
- Area under the concentration time curve [AUC]Time frame: Up to 29 days.
- Time to maximum plasma concentration [Tmax]Time frame: Up to 29 days
- Time to maximum plasma concentration [Tmax]Time frame: Up to 24 days
- Maximum plasma concentration [Cmax]Time frame: Up to 29 days
- Maximum plasma concentration [Cmax]Time frame: Up to 24 days
- Minimum plasma concentration [Cmin]Time frame: Up to 24 days
- Minimum plasma concentration [Cmin]Time frame: Up to 29 days
- C0 [predose]Time frame: Up to 24 days
- C0 [predose]Time frame: Up to 29 days
- Half-life [t1/2]Time frame: Up to 24 days
- Half-life [t1/2]Time frame: Up to 29 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PPD Austin Research Unit
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.